SAN DIEGO, June 18 /PRNewswire/ -- Kansas researchers and companies excel in the human health biosciences, and $3.7 million in new Kansas Bioscience Authority (KBA) investments in that sector will support cutting-edge innovations for the treatment of cancer, HIV, and osteoporosis, as well as in pharmaceutical development.
"Kansas has tremendous human-health research capabilities and strong corporate clustering, and we're using those strengths to address critical national and international health challenges," said KBA president Tom Thornton. "Our state's investments in highprospect companies and research projects are getting results."
The authority's new industrial investments include the following:
-- Lenexa, Kan.-based TVAX Biomedical will receive $187,622 for a clinical trial of a unique cancer treatment that uses a patient's own immune cells to fight the disease.
-- OsteoGeneX of Kansas City, Kan., will receive $375,000 for the further development of a groundbreaking treatment to stop the advance of osteoporosis and related bone disorders. This grant, which is a partial match of a $995,000 federal NIH/NIAMS Small Business Innovation Research grant, is OsteoGeneX's second award from the KBA, following a $130,000 grant last year that resulted in the identification of several bone-building small molecules.
-- ImmunoGenetix Therapeutics, Inc., Lenexa, Kan., is eligible for a $420,000 convertible note to support the development of its therapeutic vaccine for HIV designed to inhibit viral replication by enhancing antibody and cellular immune response. The KBA investment will help the company secure an equal amount of funds from other sources.
-- Vince and Associates Clinical Research, Overland Park, Kan., has
been awarded $200,000 to expand its pharmaceutical clinical research trials
capacity to meet significant increases in the demand for clinical studies.
The company is making a capital investment of over $1 million, d
|SOURCE The Kansas Bioscience Authority|
Copyright©2008 PR Newswire.
All rights reserved